Idelalisib in Relapsed CLL and Indolent Lymphoma | Now@NEJM

Retweeted NEJM (@NEJM): Idelalisib is an advance, says @danielalamasmd on our blog, because it elegantly targets v specific B-cell pathway. http://t.co/7mPNH5FDAB

via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/7mPNH5FDAB